BioGaia has today signed an agreement with the American company Victus Inc, with whom BioGaia already has a cooperation regarding distribution of a Reuteri product with Glutamine. The new agreement covers Reuteri tablets and Reuteri drops for the US hospital market. The products will be indicated to support gastrointestinal health in patients, the Reuteri tablets targetted at adults while the drops are for infants.
"The American market is still relatively undeveloped when it comes to probiotics, but in order to gain acceptance for probiotics in general and Reuteri in particular it is important that doctors start to use and recommend these kind of products. We do not expect large volumes to come immediately, but see this agreement as an important and necessary step in marketing our products in the USA" says Peter Rothschild, Managing Director, BioGaia